Genvec Inc (GNVC) 1.83 $GNVC
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST
EXXI: 2.84 (unch), EOX: 0.97 (-0.31), VTAE: 22.01 (+0.30), SN: 6.95 (-0.13), PVA: 4.84 (-0.04), ORPN: 6.71 (-0.54), LPI: 7.76 (unch), SNMX: 5.35 (+0.01), UAL: 64.10 (-1.70), RDUS: 26.38 (+1.78), GNVC: 1.83 (-0.04), GDP: 3.93 (-0.33), SFY: 3.08 (-0.09), BORN: 1.47 (+0.02), REN: 1.10 (-0.11), SCYX: 10.16 (+0.33), VGGL: 3.30 (-0.09), CMGE: 19.63 (+0.14), SLCA: 24.20 (-1.89), OAS: 12.33 (+1.28)
GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST
GNVC: 1.83 (-0.04)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 1.83 (-0.04)
GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 1.83 (-0.04)
Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 1.83 (-0.04)
GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 1.83 (-0.04)
GenVec Reports Fourth Quarter and 2013 Year-End Financial Results
PR Newswire - Fri Mar 28, 6:40AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments.
GNVC: 1.83 (-0.04)
GenVec Achieves Third Milestone In Hearing And Balance Collaboration
PR Newswire - Thu Feb 13, 5:00AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on February 7, 2014 and this triggered a $2 million milestone payment to GenVec under the terms of the collaboration.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
AutoGrid and Big Data Energy Services Announce Strategic Partnership to Deliver Demand Response (DR) Capabilities to Texas' Largest Electric Providers
Marketwire - Thu Dec 19, 6:32AM CST
AutoGrid Systems, a leader in innovative solutions for the electricity and energy industry, is proud to announce a strategic partnership with Big Data Energy Services (BDES), a cloud-based service provider and consulting firm, to deliver services and technology that will allow electricity providers to reduce the cost of power for their customers while mitigating the risk of sharply higher prices in tight energy markets.
SMSI: 0.91 (-0.03), GNVC: 1.83 (-0.04), LIVE: 2.73 (-0.15), SMRT: 14.50 (+0.01)
PowerCloud Systems and Common Sense Media Join Forces to Help Kids and Families Make Smart Choices Online
PR Newswire - Wed Dec 18, 7:00AM CST
PowerCloud Systems, a pioneer in cloud networking for the connected home, and Common Sense Media, the largest non-partisan, not-for-profit organization dedicated to helping kids thrive in a world filled with media and technology, today announced a partnership dedicated to facilitating easy access to age-appropriate Internet content in the home. PowerCloud Systems is the creator of Skydog(TM), the revolutionary home networking solution used by thousands of families to manage their connected lives by providing unprecedented visibility into, and management over, their home networks. This partnership will give Skydog users easy access to Common Sense Media's independent, age-based ratings and reviews of online media, based on developmental criteria from some of the nation's leading authorities, and provide a technical solution for the family to manage access to this media.
GNVC: 1.83 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST
EXXI: 2.84 (unch), EOX: 0.97 (-0.31), VTAE: 22.01 (+0.30), SN: 6.95 (-0.13), PVA: 4.84 (-0.04), ORPN: 6.71 (-0.54), LPI: 7.76 (unch), SNMX: 5.35 (+0.01), UAL: 64.10 (-1.70), RDUS: 26.38 (+1.78), GNVC: 1.83 (-0.04), GDP: 3.93 (-0.33), SFY: 3.08 (-0.09), BORN: 1.47 (+0.02), REN: 1.10 (-0.11), SCYX: 10.16 (+0.33), VGGL: 3.30 (-0.09), CMGE: 19.63 (+0.14), SLCA: 24.20 (-1.89), OAS: 12.33 (+1.28)
GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST
GNVC: 1.83 (-0.04)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 1.83 (-0.04)
GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 1.83 (-0.04)
Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 1.83 (-0.04)
GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 1.83 (-0.04)
GenVec Reports Fourth Quarter and 2013 Year-End Financial Results
PR Newswire - Fri Mar 28, 6:40AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments.
GNVC: 1.83 (-0.04)
GenVec Achieves Third Milestone In Hearing And Balance Collaboration
PR Newswire - Thu Feb 13, 5:00AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on February 7, 2014 and this triggered a $2 million milestone payment to GenVec under the terms of the collaboration.
GNVC: 1.83 (-0.04), NVS: 93.52 (-0.82)
AutoGrid and Big Data Energy Services Announce Strategic Partnership to Deliver Demand Response (DR) Capabilities to Texas' Largest Electric Providers
Marketwire - Thu Dec 19, 6:32AM CST
AutoGrid Systems, a leader in innovative solutions for the electricity and energy industry, is proud to announce a strategic partnership with Big Data Energy Services (BDES), a cloud-based service provider and consulting firm, to deliver services and technology that will allow electricity providers to reduce the cost of power for their customers while mitigating the risk of sharply higher prices in tight energy markets.
SMSI: 0.91 (-0.03), GNVC: 1.83 (-0.04), LIVE: 2.73 (-0.15), SMRT: 14.50 (+0.01)
PowerCloud Systems and Common Sense Media Join Forces to Help Kids and Families Make Smart Choices Online
PR Newswire - Wed Dec 18, 7:00AM CST
PowerCloud Systems, a pioneer in cloud networking for the connected home, and Common Sense Media, the largest non-partisan, not-for-profit organization dedicated to helping kids thrive in a world filled with media and technology, today announced a partnership dedicated to facilitating easy access to age-appropriate Internet content in the home. PowerCloud Systems is the creator of Skydog(TM), the revolutionary home networking solution used by thousands of families to manage their connected lives by providing unprecedented visibility into, and management over, their home networks. This partnership will give Skydog users easy access to Common Sense Media's independent, age-based ratings and reviews of online media, based on developmental criteria from some of the nation's leading authorities, and provide a technical solution for the family to manage access to this media.
GNVC: 1.83 (-0.04)
